Cowen Raises Price Target on Aquinox Pharma (AQXP) Following R&D Day
Get Alerts AQXP Hot Sheet
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
Cowen reiterated an Outperform rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and raised the price target to $24.00 (from $14.00), following the company's R&D day. AQXP presented positive Ph2 AQXP-1125 LEADERSHIP BPS/IC trial data, at the event.
Analyst Ritu Baral commented, "AQXP presented additional positive Ph2 AQXP-1125 LEADERSHIP BPS/IC trial data detail at its R&D day. We believe the proposed BPS/IC Phase 3 trial looks well designed and powered and has good chance of success, addressing a key unmet medical need. Our new $24 target (from $14) is driven by larger peak market share."
For an analyst ratings summary and ratings history on Aquinox Pharmaceutical click here. For more ratings news on Aquinox Pharmaceutical click here.
Shares of Aquinox Pharmaceutical closed at $12.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
- JPMorgan Downgrades Boyd Gaming (BYD) to Neutral
- RBC Capital Downgrades Range Resources (RRC) to Sector Perform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!